HHLA2在恶性肿瘤中的研究进展

摘要

With in-depth study on tumor pathogenesis in recent years,immunotherapy has gained breakthroughs,and Pembrolizumab,Nivolumab and other drugs,which are represented by programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1),have been approved for clinical use.Both human endogenous retrovirus subfamily H long terminal repeat associating protein 2 (HHLA2) and PD-L1 belong to B7 family and are homologous.They are highly expressed in various solid malignant tumors and are very likely to be another significant immunoassay and therapeutic target in succession to PD-L1.Research progress of HHLA2 in malignant tumors will be reviewed.%近年来,随着对肿瘤发病机制的深入研究,免疫治疗已取得突破性进展,以程序性死亡分子1(PD-1)/程序性死亡分子配体1(PD-L1)为代表的Pembrolizumab 和Nivolumab 等药物已被批准用于临床.而人内源性逆转录病毒-H 长末端重复关联蛋白2 (HHLA2)与PD-L1均为B7家族成员,具有同源性,在多种实体恶性肿瘤中均呈高表达,极有可能成为继PD-L1后的又一重要免疫检查和治疗靶点.现就HHLA2在恶性肿瘤中的研究进展做一综述.